06/22/2020 12:00 AM EDT
Source: European Union, European Centre for Disease Prevention and Control (ECDC). Published: 6/22/2020. This five-page document aims to provide guidance for public health authorities in European Union/European Economic Area countries and the United Kingdom on the ventilation of indoor spaces in the context of COVID-19. Infection control measures with proven evidence for reducing the risk of SARS-CoV-2 transmission should be emphasized. (PDF)
06/20/2020 12:00 AM EDT
Source: Centers for Disease Control and Prevention, Office of Infectious Diseases (CDC OID). Published: 6/20/2020. This web page describes the Centers for Disease Control and Prevention (CDC)’s approach to evaluating community mitigation strategies, and provides overarching considerations to support state, territorial, or local health departments; tribal health organizations; or others in monitoring and evaluating COVID-19 community mitigation strategies, including a logic model, suggested monitoring and evaluation questions, and potential data sources. (Text)
06/19/2020 12:00 AM EDT
Source: National Emerging Special Pathogens Training and Education Center (NETEC). Published: 6/19/2020. This 54-minute webinar reviews strategies used to transport COVID-19 patients and person under investigation to healthcare facilities, details efforts to address challenges, describes a methodology to increase the likelihood of identifying infectious disease risks in the workplace (Identity, Isolate and Inform), and describes strategies to prevent transmission of disease. (Video or Multimedia)
06/19/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 6/19/2020. The Food and Drug Administration has issued this 13-page guidance to provide recommendations to drug and biological product manufacturers regarding manufacturing controls to prevent contamination of drugs; risk assessment of SARS-CoV-2 as it relates to drug safety or quality; and continuity of manufacturing operations during the COVID-19 pandemic. (PDF)
06/19/2020 12:00 AM EDT
Source: San Francisco Department of Public Health (SFDPH). Published: 6/19/2020. This seven-page guidance, updated on June 19, 2020, was developed for use by shelters and navigation centers, and for people experiencing homelessness, homeless shelters, and navigation centers to prevent and manage COVID-19 transmission. (PDF)
06/18/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 6/18/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the TRUPCR SARS-CoV-2 Kit. The TRUPCR SARS-CoV-2 Kit is authorized for use with respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF)
06/18/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 6/18/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the COVID-19 Coronavirus Real Time PCR Kit. The COVID-19 Coronavirus Real Time PCR Kit is authorized for use on respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF)
06/18/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 6/18/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the Biohit SARS-CoV-2 IgM/IgG Antibody Test Kit. The Biohit SARS-CoV-2 IgM/IgG Antibody Test Kit is authorized for the detection of IgG and IgM antibodies to SARS-CoV-2 in serum, plasma (heparin, dipotassium EDTA, or sodium citrate) and venipuncture whole blood (heparin, dipotassium EDTA, or sodium citrate. (PDF)
06/17/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 6/17/2020. This seven-page letter details the Emergency Use Authorization (EUA) for the Omni COVID-19 Assay by RT-PCR for qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal swab, oropharyngeal swab, anterior nasal swab, mid-turbinate nasal swab, nasopharyngeal wash/aspirate, nasal aspirate, and bronchoalveolar lavage specimens from individuals suspected of COVID-19 by their healthcare provider. (PDF)
06/17/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 6/17/2020. This seven-page letter details the Emergency Use Authorization (EUA) for the OSUWMC (Ohio State University Wexner Medical Center) COVID-19 RT-PCR test for qualitative detection of nucleic acid from SARS-CoV-2 in nasal, oropharyngeal (OP), and nasopharyngeal (NP) swab specimens from individuals suspected of COVID-19 by their healthcare provider. (PDF)
06/17/2020 12:00 AM EDT
Source: National Institutes of Health (NIH). Published: 6/17/2020. This 58-minute presentation discusses the Australian COVID-19 experience and response, and looks back on SARS-1 vaccine development for important lessons that can inform SARS-CoV-2 vaccine design, testing, and implementation. (Video or Multimedia)
06/16/2020 12:00 AM EDT
Source: U.S. Department of Homeland Security (DHS). Published: 6/16/2020. The Department of Homeland Security has identified programmable multicookers with a sous vide function, or equivalent setting, as a suitable means to treat filtering facepiece respirators (FFRs) with moist heat at home. Moist heat decontamination is achieved by treating masks with 149°F steam for 30 minutes. This web page provides a video and documents about how to use this process. (Video or Multimedia)
06/11/2020 12:00 AM EDT
Source: ADA [Americans with Disabilities Act] National Network. Published: 6/11/2020. This one-hour, 31-minute webinar covers how a local agency has incorporated the role of the Access and Functional Needs (AFN) Coordinator into its Emergency Operations Centers, and reviews some of the activities they were involved in during the COVID-19 activation. (Video or Multimedia)
06/09/2020 12:00 AM EDT
Source: American Medical Association (AMA). Published: 6/9/2020. This series of articles offers foundational guidance in medical ethics for health care professionals and institutions responding to the COVID-19 pandemic. These articles draw on the ethics guidance of the AMA Code of Medical Ethics to help physicians meet the challenges of providing care under conditions of urgent need, limited resources, and rapidly changing scientific knowledge. (Text)
05/20/2020 12:00 AM EDT
Source: Network for Public Health Law. Published: 5/20/2020. This Frequently Asked Questions (FAQs) web page addresses questions of HIPAA compliance and requirements in regard to the COVID-19 pandemic. It is broken into 19 sections that cover waivers, disclosures, and reporting. (Text)
05/19/2020 12:00 AM EDT
Source: Network for Public Health Law. Published: 5/19/2020. The COVID-19 pandemic has raised numerous questions with regard to public health data sharing and privacy. This guidance addresses the privacy rights individuals have with regard to their personal health information that is held by a public health agency or department. (Text)
05/06/2020 12:00 AM EDT
Source: Network for Public Health Law. Published: 5/6/2020. This nine-page issue brief examines evidence of racial disparities with respect to COVID-19 infections and deaths, possible causes, and legal protections against race discrimination. It also provides an overview of crisis standards of care (CSC) planning, including key ethical features that may be utilized to ensure that CSC planning incorporates concerns about racial inequity. (PDF)
04/24/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 4/24/2020. This one-page letter authorizes the emergency use of the UDX SARS-CoV-2 Molecular Assay, which is eligible for authorization under the March 31, 2020, Emergency Use Authorization (EUA) for Molecular-based Laboratory Developed Tests for Detection of Nucleic Acid from SARS-CoV-2 (Molecular LDT COVID-19 Authorized Test). (PDF)
04/24/2020 12:00 AM EDT
Source: Network for Public Health Law. Published: 4/24/2020. Using the framing concepts and the six Moral Foundations Theory values, this three-page guidance document contains a concise way that coronavirus prevention can begin to be framed using all six different values and then adapted depending upon the audience. (PDF)
04/23/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 4/23/2020. This one-page letter authorizes the emergency use of the COVID-19 Key Assay, which is eligible for authorization under the March 31, 2020, Emergency Use Authorization (EUA) for Molecular-based Laboratory Developed Tests for Detection of Nucleic Acid from SARS-CoV-2 (Molecular LDT COVID-19 Authorized Test). (PDF)
04/22/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 4/22/2020. This one-page letter authorizes the emergency use of the Diatherix SARS-CoV-2 PCR Test, which is eligible for authorization under the March 31, 2020, Emergency Use Authorization (EUA) for Molecular-based Laboratory Developed Tests for Detection of Nucleic Acid from SARS-CoV-2 (Molecular LDT COVID-19 Authorized Test). (Video or Multimedia)
04/15/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 4/15/2020. This one-page letter authorizes the emergency use of the CirrusDx SARS-CoV-2 Assay, which is eligible for authorization under the March 31, 2020, Emergency Use Authorization (EUA) for Molecular-based Laboratory Developed Tests for Detection of Nucleic Acid from SARS-CoV-2 (Molecular LDT COVID-19 Authorized Test). (PDF)
04/15/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 4/15/2020. This one-page letter authorizes the emergency use of the CDI Enhanced COVID-19 Test, which is eligible for authorization under the March 31, 2020, Emergency Use Authorization (EUA) for Molecular-based Laboratory Developed Tests for Detection of Nucleic Acid from SARS-CoV-2 (Molecular LDT COVID-19 Authorized Test). (PDF)
04/15/2020 12:00 AM EDT
Source: Network for Public Health Law. Published: 4/15/2020. Following a brief overview of key COVID-19 epidemiology and legal updates, this one-hour, two-minute webinar centers on the key emerging constitutional challenges to ongoing public health responses in real time, based on actual litigation, policymaker objections, advocacy positions, or other sources. (Video or Multimedia)
04/14/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 4/14/2020. This one-page letter authorizes the emergency use of the Exact Sciences Laboratories SARS-CoV-2 Test, which is eligible for authorization under the March 31, 2020, Emergency Use Authorization (EUA) for Molecular-based Laboratory Developed Tests for Detection of Nucleic Acid from SARS-CoV-2 (Molecular LDT COVID-19 Authorized Test). (PDF)
Letter of Authorization: COVID-19 RT-PCR Test, Pathology/Laboratory Medicine Lab of Baptist Hospital
04/13/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 4/13/2020. This one-page letter authorizes the emergency use of the Pathology/Laboratory Medicine Lab of Baptist Hospital COVID-19 RT-PCR Test, which is eligible for authorization under the March 31, 2020, Emergency Use Authorization (EUA) for Molecular-based Laboratory Developed Tests for Detection of Nucleic Acid from SARS-CoV-2 (Molecular LDT COVID-19 Authorized Test). (PDF)
04/13/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 4/13/2020. This one-page letter authorizes the emergency use of the Integrity Laboratories SARS-CoV-2 Assay, which is eligible for authorization under the March 31, 2020, Emergency Use Authorization (EUA) for Molecular-based Laboratory Developed Tests for Detection of Nucleic Acid from SARS-CoV-2 (Molecular LDT COVID-19 Authorized Test). (PDF)
04/10/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 4/10/2020. This one-page letter authorizes the emergency use of the SDI SARS-CoV-2 Assay, which is eligible for authorization under the March 31, 2020, Emergency Use Authorization (EUA) for Molecular-based Laboratory Developed Tests for Detection of Nucleic Acid from SARS-CoV-2 (Molecular LDT COVID-19 Authorized Test). (PDF)
04/10/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 4/10/2020. This one-page letter authorizes the emergency use of the Orig3n 2019 Novel Coronavirus (COVID-19) Test, which is eligible for authorization under the March 31, 2020, Emergency Use Authorization (EUA) for Molecular-based Laboratory Developed Tests for Detection of Nucleic Acid from SARS-CoV-2 (Molecular LDT COVID-19 Authorized Test). (PDF)
04/10/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 4/10/2020. This one-page letter authorizes the emergency use of the UNC Health SARS-CoV-2 Real-Time RT-PCR Test, which is eligible for authorization under the March 31, 2020, Emergency Use Authorization (EUA) for Molecular-based Laboratory Developed Tests for Detection of Nucleic Acid from SARS-CoV-2 (Molecular LDT COVID-19 Authorized Test). (PDF)
04/08/2020 12:00 AM EDT
Source: Network for Public Health Law. Published: 4/8/2020. The COVID-19 pandemic has raised numerous questions with regard to public health reporting requirements. This guidance addresses whether domestic violence agencies or shelters have an obligation to report cases of COVID-19 to a state or local public health department. (Text)
04/04/2020 12:00 AM EDT
Source: Network for Public Health Law. Published: 4/4/2020. This two-page template details one county health department’s protocols for sharing COVID-19 identifiable patient information with first responders. (PDF)
03/31/2020 12:00 AM EDT
Source: Network for Public Health Law. Published: 3/31/2020. This four-page document provides an overview of legal and regulatory challenges to crisis standards of care (CSC) during the COVID-19 pandemic, and details how states have adopted varying CSC policies. (PDF)
03/18/2020 12:00 AM EDT
Source: Network for Public Health Law. Published: 3/18/2020. This guidance looks at how crisis standards of care (CSC) planning and guidance can help providers address critical issues that arise when health care systems are in crisis operations, including during the COVID-19 pandemic. (Text)
03/18/2020 12:00 AM EDT
Source: Network for Public Health Law. Published: 3/18/2020. This web page discusses if, and how, a HIPAA-covered health department can release COVID-19 county level case information (number of COVID-19 cases by county) to the press to avert a serious threat to public health or safety. (Text)
03/05/2020 12:00 AM EST
Source: Network for Public Health Law. Published: 3/5/2020. This one-hour webinar examines legal preparedness and response during the COVID-19 pandemic, including state and local emergency declarations and corollary public health powers; social distancing measures (e.g., quarantine, isolation, closures); and implementation of crisis standards of care. (Video or Multimedia)
No hay comentarios:
Publicar un comentario